勒波迪西兰 - 一种长时间的小干扰RNA向脂蛋白 (a)
Steven E Nissen1, Wei Ni2, Xi Shen2
1Cleveland Clinic Coordinating Center for Clinical Research, Cleveland.
The New England journal of medicine
|March 31, 2025
概括
勒波迪西兰有效降低了动脉样硬化心血管疾病患者的脂蛋白水平. 这种小干扰RNA疗法显示出血清脂蛋白度的显著,剂量依赖的降低.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 在RNA治疗方面,RNA疗法.
背景情况:
- 升高的脂蛋白[Lp[a]水平是动脉样硬化心血管疾病 (ASCVD) 的已知危险因素.
- 勒波迪西兰是一种延长时间的小干扰RNA (siRNA) 向肝脏Lp(a) 合成的安全性和有效性以前是未知的.
研究的目的:
- 评估勒波迪西兰在降低血清脂蛋白度方面的安全性和有效性.
- 为了确定莱波迪西兰在随机对照试验中的剂量反应关系.
主要方法:
- 320名参与者被随机分配,通过皮下注射接受莱波迪西兰 (16毫克,96毫克或400毫克) 或安慰剂.
- 主要终点是从60天到180天的血清Lp (a) 度与基线的时间平均百分比变化,调整为安慰剂.
主要成果:
- 勒波迪西兰在血清Lp (a) 水平上显示出显著的,剂量依赖的降低.
- 与安慰剂调整后的减少在60-180.0天之间从-40.8% (16毫克) 到-93.9% (400毫克) 之间.
- 副作用通常是轻微的,观察到剂量依赖的注射部位反应.
结论:
- 勒波迪西兰有效地降低了60至180天后的血清脂蛋白平均度.
- 这项研究支持勒波迪西兰作为一种潜在的治疗剂,用于控制升高的Lp (a) 水平并降低ASCVD风险.
更多相关视频
15:55Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
Published on: June 21, 2013
10.6K
09:48Fast and Simplified Method for High Through-put Isolation of miRNA from Highly Purified High Density Lipoprotein
Published on: July 27, 2016
11.9K
相关概念视频
siRNA - Small Interfering RNAs
16.3K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.3K
Experimental RNAi
6.0K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.0K
RNA Interference
25.8K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
25.8K
Small interfering RNAs (siRNA)
3.4K
3.4K
piRNA - Piwi-interacting RNAs
6.7K
PIWI-interacting RNAs, or piRNAs, are the most abundant short non-coding RNAs. More than 20,000 genes have been found in humans that code for piRNAs while only 2000 genes have been found for miRNAs. piRNAs can act at the transcriptional and post-transcriptional levels and have a vital role in silencing transposable elements present in germ cells. They are also involved in epigenetic silencing and activation. Previously, they were thought to function only in germ cells but new evidence suggests...
6.7K
